Tesamorelin

Overview

Tesamorelin is a stabilized analog of GHRH (specifically, a modified version of GRF 1-44) developed with enough chemical robustness to survive being broken down quickly in the bloodstream, unlike the native hormone.

Proposed Mechanism

Stimulates pituitary GHRH receptors to raise endogenous GH and IGF-1, with the most consistently documented downstream effect being a reduction in visceral adipose tissue.

Research Context

The most consistently studied research application has been reduction of visceral adipose tissue — the deep abdominal fat associated with metabolic risk, as distinct from subcutaneous fat. This specific fat-compartment effect is what distinguishes tesamorelin's research profile from other GH-axis peptides.

Evidence Status — Well-documented

The only compound in this library with a formal regulatory approval, for a specific indication (HIV-associated lipodystrophy). That approval does not extend to general research or off-label use.

Tesamorelin is the most clinically advanced compound in this research library: it has gone through the full regulatory approval pathway for a specific indication (HIV-associated lipodystrophy) in some jurisdictions. That approval is for a defined clinical use of a specific pharmaceutical product — it does not extend to general research use or any other application, and doesn't apply to research-grade material outside that approved product.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.